My Companies
Notification
Account
FY27 guidance raised: revenue ₹700Cr+, EBITDA margin 27–28%+, PAT ₹109Cr+; EPO commercialization H1FY28; Unit 6 hormones commercial production Q3FY27
No events have occurred recently